Advertisement

Topics

EMERGENT TECHNOLOGIES, INC Company Profile

17:28 EDT 24th September 2018 | BioPortfolio

Our unique process matches breakthrough technology developed at Universities or Research Institutions with commercialization partners who validate the technology and the market potential, thus reducing risk and accelerating the technology to market. We establish and manage companies that hold exclusive licenses and rights to technology that has had significant research funding and that is ready to be commercialized. Our value add is to form partnerships with large international companies pursuing major markets and managing the development process to bring the technology, products and services to market in a timely manner

Location

2508 Ashley Worth Blvd.Suite 200

Austin
Texas
78738
United States of America

Contact

Phone: 512) 263-3232
Fax: 512) 263-3236
Email: info@emergenttechnologies.com


News Articles [270 Associated News Articles listed on BioPortfolio]

Emergent BioSolutions Aqcuires Adapt Pharma and its Flagship Product Narcan

News Emergent will acquire the Narcan Nasal Spray product and a development pipeline of new treatment and delivery options to address opioid overdose.

Solving the problem of non-emergent care in the emergency department

I recently opined about a decision by Anthem to deny paying for emergency room (ER) care that it deemed to be non-emergent.  My point was that insurance companies should not be obligated to pay fo...

Emergent buys Narcan maker for $735M

Emergent BioSolutions announced that it is buying Adapt Pharma for $735 million.

Emergent BioSolutions Acquires Adapt Pharma in $735 Million Deal

Touting that it is helping fight the opioid epidemic, Emergent BioSolutions is acquiring Adapt Pharma. Under the terms of the deal, Emergent will pay $635 million up front and up to $100 million in ca...

Emergent snaps up Adapt and its opioid overdose therapy for $735m

Emergent BioSolutions has announced it has signed an agreement to acquire Adapt Pharma at a valuation of $735 million, a sum broken down into an up-front payment of $635 million and up to $100 million...

Emergent BioSolutions snaps up Narcan maker in $735M deal

Stepping into the opioid reversal market, Emergent will add an already-approved nasal naloxone to diversify its infectious disease-focused pipeline.

Emergent files paperwork for new immuno-oncology spin-off

Emergent BioSolutions announced April 15 that it has begun the formal process of separating some of its assets to form a separate entity, which will be known as Aptevo Therapeutics Inc. Read more..

Emergent gets shot in the arm with $270M deal for PaxVax

Buying PaxVax will give Emergent two FDA-approved vaccines that the company expects to generate as much as $90 million in annual sales.

PubMed Articles [454 Associated PubMed Articles listed on BioPortfolio]

Experience with Event Timing Does not Alter Emergent Timing: Further Evidence for Robustness of Event and Emergent Timing.

Although, event and emergent timings are thought of as mutually exclusive, significant correlations between tapping and circle drawing (Baer, Thibodeau, Gralnick, Li, & Penhune, 2013 ; Studenka, Zelaz...

Laparoscopic versus open emergent ventral hernia repair: utilization and outcomes analysis using the ACSNSQIP database.

Laparoscopic ventral hernia repair (VHR) is associated with decreased morbidity and shorter length of stay (LOS) when compared to open VHR. Despite evidence of the benefits of laparoscopy, its utiliza...

Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants.

Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants rais...

Monopole-Induced Emergent Electric Fields in Ferromagnetic Nanowires.

We predict that complete magnetization reversal in simple metallic ferromagnetic nanoparticles is directly linked to the pair creation of topological point defects in the form of hedgehog-antihedgehog...

Laying a Firm Foundation: Embedding Evidence-Based Emergent Literacy Practices Into Early Intervention and Preschool Environments.

As part of this clinical forum on curriculum-based intervention, the goal of this tutorial is to share research about the importance of language and literacy foundations in natural environments during...

Clinical Trials [562 Associated Clinical Trials listed on BioPortfolio]

Multifactorial Approach to Emergent Cerclage

Though cervical insufficiency is a common cause of second trimester pregnancy loss, the placement of an emergent cerclage in these patients is thought to improve perinatal outcomes. It is ...

Pre-hospital and Intra-hospital Temporal Delays in Patients Requiring Emergent Trauma Craniotomy

The investigators aim to retrospectively map the delays in the acute care of traumatic brain injury patients necessitating emergent craniotomies.

Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression

This study will develop a new methodology to evaluate any treatment-emergent suicidal ideation that might occur when an antidepressant treatment has been started and/or during times when d...

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

The goal of this study is to determine if a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) is as effective as the current standard of care. 4FPCC is used to reverse the eff...

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

This is a randomized, active comparator-controlled, parallel-group, multi-site, double-blind safety trial of sugammadex (MK-8616) for the reversal of neuromuscular blockade (NMB) induced b...

Companies [1285 Associated Companies listed on BioPortfolio]

Emergent Health Corp.

Emergent Health Corp., a diversified biotechnology firm, is focused on the health and wellness industry. Using patented and patent pending nutritionally designed products, E...

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the bodyâ€...

Emergent Financial Group, Inc.

Emergent Financial Group provides investment banking services for early stage growth companies in healthcare. By specializing on innovative healthcare companies, Emergent has deve...

Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages, develops and partners to turn game-chang...

Virtual Radiologic Corp.

Virtual Radiologic Corporation (vRad) is a national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in pa...

More Information about "EMERGENT TECHNOLOGIES, INC" on BioPortfolio

We have published hundreds of EMERGENT TECHNOLOGIES, INC news stories on BioPortfolio along with dozens of EMERGENT TECHNOLOGIES, INC Clinical Trials and PubMed Articles about EMERGENT TECHNOLOGIES, INC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EMERGENT TECHNOLOGIES, INC Companies in our database. You can also find out about relevant EMERGENT TECHNOLOGIES, INC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record